Response to upadacitinib monotherapy in a patient with eczematid-like pigmented purpuric dermatosis by Aditi Chokshi, DO, Anna Agaronov, DO, Uros Rakita, MD, MSc, Penelope Hirt, MD, Francisco Kerdel, MD

Subjects: Get full text

Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system by Shiyi Wang, Xiaojian Wang, Jing Ding, Xudong Zhang, Hongmei Zhu, Yihong Fan, Changbo Sun

Subjects: “…upadacitinib…”
Get full text

Refractory Chronic Hand Eczema Responds to Oral Upadacitinib by Nada Alghamdi, Abdullah AN.Aljalfan, Abdulmajeed S. Alharbi, Omar I.Alrubaish, Serene R.Almuhaidib

Subjects: “…Hand dermatitis, Hand Eczema, Upadacitinib, Janus kinase inhibitor.…”
Get full text

Subcutaneous immunotherapy in a patient taking ofatumumab for multiple sclerosis and upadacitinib for atopic dermatitis by Twan Sia, BA, Leeon Bacchus, BA, Stanley Liu, BS, John Leung, MD

Subjects: Get full text

An Analysis of the Effectiveness and Safety of Upadacitinib in the Treatment of Inflammatory Bowel Disease: A Multicenter Real-World Study by Hongzhen Wu, Tingting Xie, Qiao Yu, Tao Su, Min Zhang, Luying Wu, Xiaoling Wang, Xiang Peng, Min Zhi, Jiayin Yao

Subjects: “…upadacitinib…”
Get full text

Successful Achievement of Demanding Outcomes in Upadacitinib-Treated Atopic Dermatitis Patients: A Real-World, 96-Week Single-Centre Study by Stamatios Gregoriou, Ioannis-Alexios Koumprentziotis, Ileana Afroditi Kleidona, Michail Bakakis, Eleni Hatzidimitriou, Theodora Douvali, Aikaterini Tsiogka, Styliani Mastraftsi, Aristeidis Vaiopoulos, Alexander Stratigos

Subjects: Get full text

Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study by Filip Van den Bosch, Atul Deodhar, Denis Poddubnyy, Walter P. Maksymowych, Désirée van der Heijde, Tae-Hwan Kim, Mitsumasa Kishimoto, Xenofon Baraliakos, Xianwei Bu, Ivan Lagunes-Galindo, In-Ho Song, Peter Wung, Koji Kato, Anna Shmagel

Subjects: Get full text